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Abstract
Background: Inhaled glucocorticoids are efficient in protecting against asthma exacerbations, but methods to
compare their efficacy vs systemic effects have only been attempted in larger multi-centre studies. The aim of the
current study was therefore to directly compare the effects of two separate inhaled glucocorticoids, mometasone
and budesonide, to compare the effects on the early and late asthmatic responses to inhaled allergen in patients
with mild allergic asthma, and sputum eosinophils, and to relate the clinical positive effects to any systemic effects
observed.
Methods: Twelve patients with documented early and late asthmatic responses (EAR and LAR) to inhaled allergen
at a screening visit were randomized in a double-blind fashion to treatment with mometasone (200 μg × 2 or 400
μg × 2), budesonide (400 μg × 2) or placebo in a double-blind crossover fashion for a period of seven days.
Challenge with the total allergen dose causing both an EAR and LAR was given on the last day of treatment taken
in the morning. Lung function was assessed using FEV1, and systemic glucocorticoid activity was quantified using
24 h urinary cortisol.
Results: Mometasone and budesonide attenuate both EAR and LAR to allergen to a similar degree. No significant
dose-related effects on the lung function parameters were observed. Both treatments reduced the relative amount
of sputum eosinophils (%) after allergen. At the dose of 800 μg daily, mometasone reduced 24 h urinary cortisol by
approximately 35%. Both drugs were well tolerated.
Conclusions: Mometasone and budesonide are equieffective in reducing early and late asthmatic responses
induced by inhaled allergen challenge. Mometasone 800 μg given for seven days partially affects the HPA axis.
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Background
Asthmatic patients with allergies often develop early
(EAR) and in some patients also a late asthmatic
response (LAR) when a relevant allergen is inhaled
[1-3]. Allergen exposure can also increase non-specific
bronchial hyperresponsiveness to stimuli such as metha-
choline or histamine [4]. The LAR and the bronchial
hyperresponsiveness are often associated with increase
of eosinophils in the blood, and influx of eosinophils
into the airways [3,5].
The anti-inflammatory effects of inhaled glucocorti-
coids in asthma are well documented [1,6,7], shown by
attenuation of the EAR, LAR and allergen-induced spu-
tum eosinophils. Glucocorticoids are also more effective
than anti-leukotrienes in attenuating the LARs and
improve the bronchial hyperresponsiveness in mild asth-
matic patients [8]. Mometasone and budesonide are
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cant effect on late events induced by allergen, including
attenuation of the LAR and reductions in eosinophil
and neutrophil recruitment and activation [5,9,10].
The aim of the present study was to directly compare
the effects of inhaled mometasone with inhaled budeso-
nide and placebo on allergen-induced airway responses
in mild asthmatic patients. Treatments were given for
seven days and the allergen challenge was performed on
Day 7 of treatment. Lung function was measured to
assess the development of EAR and LAR. Sputum and
blood were analysed in order to assess inflammatory
processes. To determine whether any differences in sys-
temic effects of the drugs could be detected, urinary
cortisol was measured.
Materials and methods
Patients
Twelve patients (Table 1) with mild allergic asthma,
only occasionally using inhaled beta-2-agonists when
need arises, were included in the study. The presence of
both an early and a late asthmatic reaction after allergen
challenge had to be evident in each patient. That is to
say the patients had to develop an early asthmatic reac-
tion, EAR, (a fall in FEV1 of at least 20% from baseline
within an hour) and a late asthmatic reaction, LAR, (a
fall in FEV1 of at least 15% from baseline on at least one
time point during 4-7 h) after bronchial allergen
challenge.
Exclusion criteria were inability to produce sputum
after inhalation of hypertonic saline, ongoing treatment
with inhaled or oral glucocorticoid or long-acting
inhaled b-2-agonist, ongoing smoker and pregnancy.
Patients with other significant diseases were also
excluded.
Study design
This was a randomized, double-blind, placebo-con-
trolled, cross-over study at one single centre. Approval
was obtained by the Swedish Medical Product Agency
and the Local Ethics Committee. Written informed con-
sent was received form all patients before enrolment. All
patients received four different interventions including
mometasone 2 × 200 μg, mometasone 2 × 400 μg, bude-
sonide 2 × 400 μg and placebo with one week wash-out
between treatments. The study was performed during
2001-2003, before the requirement to register clinical
trials in clinicaltrials.gov.
The treatment and challenge protocol is described in
Figure 1. All patients were screened during two days.
At the screening visit a bronchial allergen challenge
was performed. Twenty-four hours later the metha-
choline responsiveness was tested just prior to the
sputum induction. If all inclusion/exclusion criteria
were met the patient was randomised on the second
day.
The study medication for one treatment period was
brought home by the patient and the study treatment
was initiated after a telephone contact with the patient
one to two weeks after randomisation. Study medica-
tions were given as one dose in the morning and eve-
ning for 7 days (only in the morning on Day 7).
The patient returned to the clinic on day 7. The
cumulative allergen dose titrated on the screening day
was given as a single dose allergen challenge (after the
morning dose of inhaled treatment) in each treatment
period. Induction of sputum was performed 24 h after
allergen challenge.
Allergen challenge
Allergen extracts (cat, dog, or horse) from Copenhagen
Allergology Laboratory (ALK), Copenhagen, Denmark,
were used. The screening allergen provocation protocol
started with the diluents, and the pre titrated allergen
dose given was 32 standard quality units (SQU/ml).
There was a twofold increase between every dose step.
The highest allergen dose was 64 000 SQ-U/ml. FEV1
was measured 5 and 10 min after each dose (the best of
two manoeuvres with 1 min between). When FEV1 had
f a l l e na tl e a s t2 0 %f r o mt h eb a seline value, the allergen
provocation was stopped (EAR). After the last allergen
dose FEV1 was measured at 15, 20, 30, 45 and 60 min
during the first hour, and then every hour up to 10 h.
The cumulative allergen dose titrated on the screening
day was given as a single dose on day 7 in all four treat-
ment periods. The FEV1 was measured at the same
time-points as above.
The LAR was defined as a fall in FEV1 of 15% from
baseline value on at least one time point between 3 and
7 h after the allergen dose that caused the EAR.
Table 1 Characteristics of the patients
Patient no. Sex Age (years) FEV1
(L)
Baseline
Allergen
1 F 44 2.71 Cat
2 M 33 3.61 Cat
3 M 28 3.56 Cat
4 F 31 2.70 Cat
5 F 43 2.81 Cat
6 F 20 3.46 Cat
7 M 30 3.60 Cat
8 F 26 3.59 Cat
9 M 36 3.70 Cat
10 F 34 2.28 Equine
11 M 27 3.81 Canine
12 M 40 3.96 Cat
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Methacholine challenge was performed 24 h after the
allergen challenge at the screening and on Day 8. At a
starting concentration of 0.03 mg/ml, twofold increasing
concentrations were administered every fifth minute.
FEV1 was measured at 90 and 180 s after the inhala-
tions. When FEV1 had fallen with ≥ 20%, the provoca-
tion was stopped (Provocative Concentration changing
FEV1 by 20% = PC20).
Bronchial challenge
The dosimeter ME.FAR MB3 (Mefar, Brescia, Italy) was
used for all bronchial challenges (allergen and metha-
choline). The patient inhaled slowly the dose of aerosol
by means of an inspiratory capacity breath, followed by
5 s of breath holding. For each dose of allergen or
methacholine, five inhalations were given. The nebuliza-
tion time was set to 1 s. The patients were instructed to
use a home spirometer (One Flow soft 1.0 from STI) for
the FEV1 measurements 1 h to 10 h after allergen
exposure.
Sputum induction
Sputum induction was performed using a modification
of the method of Pin et al. [11] with an aerosol of
hypertonic saline. Inhalations started with 3% concentra-
tions of saline for 7 min. If FEV1 had dropped less than
10% from baseline, the next saline concentration (4 and
5%, respectively) was administered. If the fall in FEV1
was between 10 and 20% from baseline, the same saline
concentration was given for the next 7 min. The nebuli-
zation was stopped if the fall in FEV1 was more than
2 0 %f r o mb a s e l i n e .T h es p u t u mw a sc o u g h e du pi n t oa
container and further analysed. After the sputum induc-
tion at the screening and on day eight, a single oral
dose of 30 mg of prednisolone was given to reverse any
remaining effects on LAR, as used previously [8].
Sputum cell analysis
Sputum samples were examined within 2 h (kept cold)
using a modified method described by Pizzichini et
al.1996 [12-14]. Sputum cells were prepared as described
earlier and the total number of cells and cell viability
was assessed [8]. Percentage of eosinophils (%) were
identified by differential counts using a combination of
luxol fast blue and chloroacetate esterase staining.
Other analyses
Samples for blood eosinophils and ECP were collected
at the screening and on day 7 both before and 24 h
after allergen challenge. Urinary samples for analysing
cortisol and creatinine analyses were collected 24 h post
allergen (Day 8).
Statistics
Power calculations showed that less than five patients
are required to document a 50% reduction of LAR with
90% power [15,16]. To document a similar reduction of
sputum eosinophils (%), a similar number of patients are
required [17]. Therefore, a study including twelve
Day 8 Day 7
x
TREATMENT (x)
T
x
x
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SPUT-EOS
PC20
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B-ECP
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PC 20
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-1 to -2 weeks
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Figure 1 Schedule for each treatment period. Treatments were taken each morning and evening, and in the case of mometasone 400 μg,
only once daily.
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sons were made using student’s paired t-test, and a p-
value < 0.05 was considered statistically significant.
Results
All twelve subjects who entered the study (Figure 1) also
completed all the four arms of the crossover study.
There was no significant difference between treatment
groups in baseline FEV1 prior to allergen; the values
were 3.30 L after placebo, 3.40 L after Mometasone (400
μg), 3.38 L after Mometasone (800 μg) and 3.30 L after
treatment with budesonide (800 μg).
Early allergen response (EAR)
Allergen challenge during the placebo treatment pro-
duced an immediate reduction in FEV1 reaching
-13.9% at 15 min (Figure 2). The AUC for the EAR
was 3.06 after placebo, 3.25 after the lower dose of
mometasone, 3.26 after the higher dose and 3.15 after
budesonide. Both concentrations of mometasone
showed a significant difference in AUC EAR in com-
parison with placebo (P = 0.026, P = 0.017), but the
effect of budesonide treatment was not statistically sig-
nificant (P = 0.150). The maximum mean drop in
FEV1 during the EAR was 8.37% after 20 min at the
low dose and 7.15% after 15 min at the high dose of
mometasone. The corresponding FEV1 value in the
budesonide group was 10.0% after 15 min. The maxi-
mal drop in EAR was significantly less after the higher
dose of mometasone vs budesonide (P = 0.02), but not
significantly between the lower dose of mometasone vs
budesonide (P = 0.06). There was no statistical differ-
ence between the effects of two different concentra-
tions of mometasone on the EAR.
Late asthmatic response (LAR)
Allergen challenge during the placebo treatment pro-
duced a late reduction in FEV1 reaching a maximum
of 7.1% at 10 h. The AUC for the LAR between 1 to
10 h was 3.03 L after placebo, 3.18 L after the low
dose of mometasone, 3.19 L after the high dose and
3 . 1 3La f t e rb u d e s o n i d e( F i g u r e3 ) .T h eh i g h e rd o s eo f
mometasone showed a significant change in AUC of
the LAR in comparison with placebo (P = 0.04), but
the two other treatments did not significantly change
the LAR, although tendencies were observed (mometa-
sone 400 μg: P = 0.065, budesonide: P = 0.076). During
mometasone treatment, the maximum late drop in
FEV1 was 5% at 10 h during treatment with the low
dose and 2.6% after 8 h during treatment with the
higher dose. The corresponding FEV1 value in the
budesonide group was 3.9% a f t e r9h .T h e r ew e r en o
significant differences among the different treatments
for the LAR.
Methacholine responsiveness
Twenty-four hours after allergen challenge the metha-
choline PC20 was 6.3, 11.1, 16.7 and 9.9 mg/ml during
placebo, 400 μg mometasone, 800 μg mometasone and
800 μg budesonide treatment respectively. The result in
all three treatment groups was statistically different
from placebo. The low and high doses of mometasone
reduced methacholine responsiveness with 2.6 and 2.8
doubling doses respectively in relation to placebo treat-
ment (P = 0.004, P = 0.011), and the treatment with
budesonide resulted in a doubling dose shift of of 2.4 vs
placebo (P = 0.005). No significant differences were
observed among treatments.
Eosinophils
Sputum and blood were collected for the evaluations of
eosinophils after allergen. There was a reduction of spu-
tum eosinophils in all active treatment groups at 24 h
after allergen provocation (Figure 4). The percentage of
eosinophils in sputum was 14.6 ± 2.9 after placebo, 4.9
±1 . 6a f t e r4 0 0μg mometasone, 4.8 ± 1.6 after 800 μg
mometasone and 5.6 ± 1.7 after budesonide. Sputum-
eosinophils were significantly decreased in all three
treatment arms in comparison with placebo (p < 0.05),
but no significant differences were observed among the
active treatments. The number of blood eosinophils
tended to be reduced in comparison with placebo after
mometasone and budesonide both at 7 and 24 h (data
not shown), but there were no differences observed
among treatments.
Urinary analysis
The detailed results of efficacy and urinary cortisol and
other efficacy parameters are listed in Table 2. The 24 h
urinary level of cortisol concentration was 215 ± 74, 179
± 16, 135 ± 14, and 201 ± 38 nmol/L after treatment
with placebo, 400 μg mometasone, 800 μg mometasone
and 800 ug budesonide respectively. In the higher dose
group of mometasone the cortisol level was significantly
reduced (P < 0.001). A significant difference was also
observed between the two dose levels of mometasone (P
= 0.003), but not between the high dose of mometasone
and budesonide (P = 0.07).
Discussion
This cross-over double blind placebo controlled study
shows that one week treatment with both Mometasone
400 and 800 μg and Budesonide 800 μg affected physio-
logical early and late asthmatic responses induced by
inhaled allergen provocation, as well as inflammatory
markers such as sputum eosinophils. The data suggests
that Mometasone was more effective in attenuating the
early asthmatic response than budesonide was at the
same microgram daily doses. Furthermore, methacholine
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nificantly improved with all treatments. In parallel,
effects of the inhaled glucocorticoids on serum cortisol
was evaluated to determine airway effects vs systemic
effects, showing only significant reduction of this para-
meter with the higher dose of mometasone.
This direct comparison between mometasone and
budesonide suggests very similar inhibitory effects on
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Figure 2 Time course of FEV1 up to 1 h, % of baseline, and absolute FEV1, after inhaled allergen exposure during the different
treatments arms (placebo, mometasone 400 μg, mometasone 800 μg and budesonide 800 μg daily).
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Page 5 of 9allergen induced physiological responses in asthmatic
patients with these two inhaled glucocorticoids,
although mometasone at the higher dose cause a signifi-
cantly greater inhibition of the early asthmatic response.
The reduction of both the early and the late asthmatic
response with the treatments was similar to what can be
observed with other inhaled glucocorticoids [6,8,16]. It
must be recognized that our main aim was to relate
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Figure 3 Time course of FEV1 up to 10 h after inhaled allergen exposure during the different treatments arms (placebo, mometasone
400 μg, mometasone 800 μg and budesonide 800 μg daily).
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high doses of inhaled glucocorticoids were tested. Thus,
it may be difficult to compare the exact potency of
t h e s ed r u g s ,a sn of u l ld o s er e s p o n s ec o u l db ep e r -
formed with this complicated provocation protocol. In
fact, such a full dose-response evaluation has not been
reported with any inhaled glucocorticoid on allergen-
induced asthma responses to date.
The three different active treatments all significantly
and strongly reduced the sputum eosinophilia observed
0 
10 
15 
5 
PLA MOM 
800 
MOM 
400 
BUD 
800 
Sputum EOS (%) 
Figure 4 Sputum eosinophils (%) 24 h after inhaled allergen exposure during the different treatments arms (placebo, mometasone
400 μg, mometasone 800 μg and budesonide 800 μg daily).
Table 2 Comparison between treatments
Analysis
Means (SD)
Placebo Mometasone
400 μg
Mometasone
2 × 400 μg
Budesonide
2 × 400 μg
Sputum-EOS
(%)
14.60 (9.49) 4.94 (5.45) 4.83 (5.48) 5.66 (5.55)
B-EOS (10
9/L) 0.32 (0.20) 0.22 (0.12) 0.18 (0.08) 0.20 (0.13)
S-ECP (μg/L) 13.24(13.56) 10.21 (8.80) 8.35 (7.97) 8.83 (8.39)
PC20 (mg/ml) 6.30 (10.77) 11.12(10.56) 16.72 (18.33) 9.88 (11.34)
U-Cortisol (nmol/L) 214.55 (74.19) 179.20 (55.80) 135.11 (49.39) 204.08 (130.45)
U-Creatinine (mmol/L) 12.91 (3.59) 13.86 (3.61) 12.90 (3.42) 12.92 (3.27)
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observed between them. This argues that both drugs
and the doses tested are sufficient to efficiently attenu-
ate the inflammatory response associated with the late
asthmatic response, as has been previously documented
[2,9,18]. The exact mechanism by which inhaled gluco-
corticoids have such pronounced effect on eosinophilic
inflammation are not clear, although inhibitory effects
on T-lymphocyte responses may be crucial [19].
Methacholine responsiveness, measured 24 h after the
allergen provocation, was significantly attenuated by
both doses of mometasone, as well as the single studied
dose of budesonide. Importantly, this attenuation of
bronchial hyperresponsiveness has two components to
it. Firstly, the inhaled glucocorticoid significantly
improves baseline bronchial hyperresponsivness [20,21],
and secondly, it is also known that inhaled glucocorti-
coids can attenuate the increase in hyperresponsiveness
induced by allergen exposure [15,16,22,23]. Thus, the
attenuation of hyperresponsiveness observed in the cur-
rent study is a composite effect of the inhaled glucocor-
ticoid therapy on general bronchial hyperresponsiveness
and the increased hyperresponsivness induced by the
experimental allergen exposure. It is unlikely that the
two studied inhaled glucocorticoids have fundamentally
and mechanistically different effects on these separate
explanations for the methacholine responsivenss value
measured 24 h after allergen exposure.
With both doses of mometasone, and the single dose
of budesonide studied, pronounced and highly signifi-
cant inhibitory effects on allergen-induced sputum eosi-
nophils were observed, and no dose-related effects of
mometasone were obvious. This argues that the doses of
inhaled glucocorticoids used in the current study was
quite high for attenuating sputum eosinophils, and
arguing that the anti-inflammatory efficacy of the doses
studied were high.
Quite high doses of inhaled glucocorticoids were stu-
died, to add the potential of studying also systemic
effects of the two different inhaled glucocorticoids.
Furthermore, we decided to study two doses of mometa-
sone, to allow for documentation of some dose-related
effects on either anti-asthma effects or systemic effects.
Indeed, some differences in both airway and systemic
effects were observed, with greater inhibition on the
early asthmatic response with the higher dose of mome-
tasone. However, in parallel a slightly increased effect
on 24 h urinary cortisol was observed, which thus
means that the higher dose of mometasone also
expressed some systemic effects. Thus, the additive
e f f e c tw i t ht h eh i g h e rd o s eo fm o m e t a s o n ew a sa s s o -
ciated with greater systemic effect, arguing against any
major difference in therapeutic ratio between the two
different inhaled glucocorticoids.
In summary, both mometasone and budesonide at the
doses studied (daily doses 400 and 800 μg for mometa-
sone and 800 μg for budesonide) are highly effective in
attenuating allergen-induced immediate airway
responses, and strongly attenuate eosinophilic inflamma-
tion in the airways. Increased efficacy in the airways with
the higher dose of mometasone was associated with a
slightly higher degree of systemic effects, suggesting that
increasing the dose is not necessarily associated with an
improved therapeutic ratio. Inhaled glucocorticoids are
efficient anti-inflammatory treatments in allergic asthma,
and documenting any key differences in therapeutic
effects and therapeutic ratio may deem difficult.
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